CancerFree's proprietary E.V.A. (Ex Vivo Avatar) system cultivates organoids from as little as 20mL of a patient’s blood, creating a “tumor avatar” that closely replicates the individual’s own cancer. This allows for rapid and personalized drug sensitivity testing, helping clinicians recommend the most effective therapies while minimizing the risks of trial-and-error drug use for cancer patients. By combining advanced cell culture with AI image recognition, the E.V.A. platform supports applications in precision medicine, cell therapy, cancer vaccine development, and drug discovery. CancerFree Biotech’s technology has been validated across over 1,500 patient cases and more than 100 solid tumor types, with established partnerships in Taiwan and expansion underway in Japan. Their mission centers on reducing patient suffering and improving treatment outcomes by placing scientific rigor and patient needs at the core of cancer care.
Testimonial
Related Companies
Klona Biotech
The future of human tissue replacements using 3D printing
London, United Kingdom
Lyric Bio
Pioneering the future of biomanufacturing using proven and proprietary 3D bioprinting and tissue engineering technologies
San Carlos, California
Eywa Biotech
Scaling the production of pharmaceutical-grade psychedelic compounds through synthetic biology
Montevideo, Uruguay · Buenos Aires, Argentina
PrettyLitter
Develops a lightweight cat litter that helps cat owners monitor their pets' health by changing colors in response to abnormalities in urine.
Los Angeles, United States
nVision
nVision’s focus is on women’s health. The company created the first FDA-cleared device for collecting cells from the fallopian tubes, which aimed to enable earlier diagnosis of ovarian cancer. In 2018, nVision was acquired by Boston Scientific.
Senodia
MEMS sensors for various applications.
China, Shanghai
Aanika
Innovative science-backed insurance solutions for agriculture and food industries with Bio technology.
Brooklyn, United States
